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INTRODUCTION: To capitalise on the opportunities that
the smoking ban legislation in Switzerland offers for the
prevention of tobacco-related diseases, a smoking ces-
sation programme in a workplace setting was developed
and implemented in companies across the language and
cultural regions of Switzerland. Our goal was to identify
factors associated with relapse into smoking that may be
overcome during training sessions or that should be con-
sidered for the optimisation of future interventions.
METHODS: Between 2006 and 2012, 1287 smokers aged
16 to 68 years voluntarily attended smoking cessation
training at their workplace. The intervention was based on
a cognitive behavioural group therapy combined with in-
dividual proactive telephone counselling. The evaluation
consisted of three anonymised questionnaires (pre- and
postintervention, and 12-month follow-up). In this prospec-
tive cohort study, we investigated the association of smok-
ing quit rates with training and participant characteristics,
including withdrawal symptoms, by use of multilevel logis-
tic regression analysis with a random intercept for training
courses.
RESULTS: The self-reported abstinence rate was 72.4%
at the end of the training, and 18.6% 1 year later. The risk
of relapse during the training was positively associated
with the number of years and daily cigarettes smoked, and
negatively with increased appetite, sleeping troubles and
satisfaction with learned techniques. Failed abstinence
within the first year was associated with younger age,
higher numbers of daily smoked cigarettes and unsuc-
cessful recent quit attempts.
CONCLUSION: Our evaluation suggests that younger and
more addicted smokers attending smoking cessation train-
ings may need additional support to achieve long lasting
abstinence rates. Offering smoking cessation training in a
workplace setting can achieve reasonable long-term quit
rates, but a subset of employees needs additional support
at the group or personal level.
IMPLICATIONS: Group behaviour therapy could be an ef-
fective method to achieve long-term smoking abstinence.
The workplace is an important setting to reach and en-
courage a large number of smokers to participate in a
smoking cessation programme, but only few studies inves-
tigated its potential. The findings of this study of a modern
real-life workplace-based smoking cessation programme
endorse the effectiveness and viability of cognitive behav-
ioural group therapy. This group-level intervention at the
workplace may be insufficient for young and heavy smok-
ers, as well as women with increased appetite after cessa-
tion, who potentially benefit from re-intervention and addi-
tional individual level counselling.
Key words: psychotherapy, group, behaviour therapy,
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Introduction
In 2012, 25.9% of the Swiss population above the age of
15 were smokers [1]. In Switzerland, smoking accounts
for approximately 9000 deaths each year and for economic
damage of up to 10 billion Swiss francs from medical treat-
ment costs, losses in productivity and intangible costs (loss
of quality of life, years of life lost) [2, 3]. Smoking cessa-
tion is associated with a reduction of total morbidity and
mortality related to cardiovascular diseases, chronic ob-
structive pulmonary diseases and lung cancer [4].
Group behavioural therapy is considered effective for
achieving long-term smoking abstinence and thereby pre-
venting tobacco-related diseases [5, 6]. Group interven-
tions might also be more cost-effective than more expen-
sive interventions for single smokers, because of the better
use of the trainers’ time [7]. Group interventions further-
more offer a setting of social learning and the possibility to
share experiences, encourage and support each other, po-
tentially increasing members' supportive social networks,
which may contribute to satisfactory cessation rates [8, 9].
As most people spend about a third of their day at work, es-
tablished communication channels in this setting can reach
and encourage a large number of smokers to participate
in a smoking cessation programme. Participants could also
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benefit from sustained peer group support and positive
peer pressure within the company. Other advantages are
the proximity of the training to the workplace and the op-
portunity for companies to support the health of their em-
ployees [10].
Shortly after Switzerland signed the WHO Framework
Convention on Tobacco Control (FCTC) in 2004, the Lung
Association Basel launched the project “Enterprise
Smoke-free” (“Unternehmen rauchfrei”), which supports
companies interested in regulating smoking at their work-
places [11, 12]. A smoking cessation programme for a
workplace setting was developed in collaboration with the
Institute for Therapy Research (IFT) in Munich and im-
plemented in the various language regions of Switzerland
[13]. The programme was further strengthened in 2010,
when a nationwide law that limits second-hand smoke ex-
posure in most workspaces and public indoor areas was
implemented [14].
Our hypothesis was that demographic and personal char-
acteristics, as well as the social environment (e.g., family,
friends, and co-workers), of the participants have a direct
and indirect influence on their motivation to stop smoking
and on short- or long-term abstinence failure. Additionally,
we expected that some external factors, such as training,
trainer and company characteristics, withdrawal symptoms
and use of pharmacotherapy influence relapse rates.
The hypothesis was built in the light of the following evi-
dence from cessation interventions different from ours. De-
mographic determinants such as gender, age, body mass in-
dex and work function (as a marker for education status)
have been shown to be directly associated with abstinence
failure [15–19]. Smoking characteristics known to influ-
ence smoking cessation include years of smoking, number
of cigarettes smoked per day and time of first cigarette
smoked after waking up [16, 20–22]. Motivation factors
such as intention to stop smoking, previous smoking ces-
sation attempts and incentives, including provision of costs
or time for training by employer, were reported to have
an impact on smoking relapse [23–26]. There are only
a few studies describing the association between relapse
rates and training characteristics such as training structure,
group size and trainer gender [8, 27]. The effect of with-
drawal symptoms and weight gain are well documented
and have a significant impact on abstinence failure [28,
29]. Additionally, pharmacotherapy has been shown to
help prevent smoking relapse [30].
The ultimate objective of this current analysis was to iden-
tify groups of smokers at increased risk of abstinence fail-
ure in this specific workplace-set intervention, who would
benefit from additional support before or during training
sessions.
Methods
Study design
This prospective cohort study was part of an evaluation
programme mandated by the Swiss Tobacco Prevention
Fund to assess accountability and quality of smoking ces-
sation courses within the Enterprise Smoke-free pro-
gramme.
The participants were contacted at their workplace through
internal newsletters, intranet news, posters and flyers.
Three anonymised questionnaires were distributed to par-
ticipants: at the beginning of, the end of, and 12 months
after the end of the training. To improve the response rate
for the 1-year follow-up questionnaire, participants were
reminded first with a letter, then by up to three phone calls
and, more recently, also by e-mail.
All participants were informed, orally in the first session
and again in writing at later time-points, about the scien-
tific evaluation and confidential data handling. Participa-
tion in the programme was voluntary, and written informed
consent was obtained from all subjects. The joint ethics
committee of northwest and central Switzerland (EKNZ)
approved this study based on the evaluation data in April
2015.
Intervention
Enterprise Smoke-free is a cognitive behavioural group
therapy combined with up to three individual proactive
telephone counselling calls of up to 10 minutes each. The
structure and content of the programme is described in
table 1. Enterprise Smoke-free is based on the commonly
used multicomponent treatment programme, including a
fixed quit day, social support, motivational enhancement,
lifestyle changes, coping techniques for risk situations, and
relapse prevention [31]. It was enhanced by elements from
psycho-education, and change- and acceptance-oriented
psychotherapy methods, including clarification of goals,
imagination rehearsal, acceptance strategies, skills train-
ing, emotion regulation and stress tolerance [32, 33]. Phar-
macotherapy was not a standard component of the cessa-
tion therapy, but its use was not actively discouraged.
On the basis of the standard programme (six weekly ses-
sions of 90 minutes), compact (4 weeks, three sessions of
180 minutes) and super-compact (two weekly sessions of
270 minutes) versions were developed at the request of two
big companies, for organisational reasons. Irrespective of
programme type, a quit day is fixed in the middle of the
programme. Training types differ in the number of sessions
and time between quit day and end of the training, but not
in their content or total contact time of 540 minutes.
Trainers were certified after attending an extensive stan-
dardised training seminar according to the IFT model. To
maintain high training quality, highly structured manuals
were distributed to the trainers and they have to attend an
annual advanced training session [5].
The only incentive for participants to join the programme
was the waiving of the training fee, offered by most com-
panies. Only a few companies linked fee reimbursement to
successful abstinence during the training.
Study population
Figure 1 shows the flow chart of study participants. All
participants who voluntarily attended the Enterprise
Smoke-free smoking cessation training at their workplace
between 16 February 2006 and 25 September 2012 were
included in this study. The study population therefore con-
sisted of 1287 smokers aged 16 to 68 years.
Questionnaire information
Sociodemographic characteristics, smoking behaviour,
motivation to quit, training and health data were taken
from the questionnaires developed by the IFT and con-
densed for evaluation purpose by the Lung Association
"91/16)4)9;1+4- Swiss Med Wkly. 2017;147:w14500
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 2 of 15
Basel and the Swiss Tropical and Public Health Institute
Basel [5].
Outcome measures
First, we identified the postintervention and 1-year quit
rates as outcomes. The study sample used to describe the
quit rate consisted of all 1287 participants. Abstinence was
1/<9-
 Flow chart of study participants
thereby defined in accordance with the Russell Standard
defining criteria for the standard evaluation of abstinence
rate of smoking cessation interventions [34]. The Russell
Standard consists of: a follow-up for 6 or 12 months; self-
reported abstinence allowing up to five cigarettes in total;
biochemical verification of abstinence at follow-up; and
use of an intention-to-treat approach in which data from
the full sample of all smokers are included in the analy-
sis unless they have died or moved to an untraceable ad-
dress. According to the Russell Standard and in our study,
nonabstinence was defined as self-reported nonabstinence
for persons smoking more than five cigarettes in total since
the quit day [34]. Dropouts from the training, nonrespon-
ders to the postintervention questionnaire, persons lost to
follow-up, and persons who refused to participate in one
of three evaluation questionnaires or had missing data on
abstinence at the postintervention assessment and at 1-year
follow-up were classified as nonabstinent at postinterven-
tion and after 1 year, respectively. This is a conservative
approach to avoid overestimation of therapy benefits due
to the higher likelihood of non-quitters being lost to fol-
low-up. We also took into account a trichotomous out-
come variable with levels “smoking abstinence”, “nonab-
stinence”, and “nonresponse at the 1-year follow-up” to
specifically examine the reasons for nonabstinence or non-
response.
Second, we investigated risk factors for nonabstinence
from smoking at the postintervention assessment and at 1
year as outcomes. The study sample to investigate predic-
tors of smoking relapse consisted of 840 participants on-
ly; 447 participants were excluded because of incomplete
pre- and postintervention variables, missing information
about postintervention abstinence, unreliable information
about abstinence (declaration as not abstinent or informa-
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 Training structure and content.
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Information event Information about smoking and cessation
programme.
Motivating to participate.
Offering decision support.
1 Cognitive preparation, motivation,
psycho-education
Quiz about smoking and non-smoking. Lec-
ture on smoking, non-smoking and passive
smoking. Self-monitoring of smoking behav-
iour.
2
1
Motivation, reinforcing ambiva-
lence, self-control
Collecting arguments pro-smoking and pro-
smoke-free-living.
Personal gain of smoke-free-living.
Motivation, psycho-education,
coping skills, behavioural alterna-
tives to smoking
Lecture on the functioning of smoking in de-
pendent smokers. Identification of smoking
situations. Alternatives to smoking.
Information on nicotine replacement.
Coping skills, self-management Preparation for quit day. Lecture on strate-
gies to cope with craving.
Preparation
3 2
1
Quit day Stop smoking.
Proactive telephone counselling Talking about individual situations.
4
5
Relapse prevention, positive rein-
forcement, psycho-education
Exchange of experiences.
Lecture on lapse and relapse.
Lecture on withdrawal symptoms. Rewards
for smoke-free living.
6
3 2
Relapse prevention, positive rein-
forcement, imagination
Exchange of experiences.
Developing a non-smoker’s identity. Retro-
spection. Planning the smoke-free future.
Stabilisation
Proactive telephone counselling Talking about individual situations.
Developed in collaboration with the Institute for Therapy Research (IFT).
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tion missing at postintervention but as abstinent at follow-
up), and other inaccurate information.
Independent variables
The risk factors for nonabstinence were grouped into so-
ciodemographic determinants, smoking determinants, mo-
tivational determinants and training determinants at base-
line (see table 2 below for specific variables in these
groups), as well as into health determinants and training
determinants at postintervention (see table 3 for specific
variables in these groups).
Among the sociodemographic determinants, the work
function of the training group was used to classify partic-
ipants into raw socioeconomic groups because of missing
detailed information on education and income of the in-
dividual participants. Smoking determinants were selected
and partly classified according to the Fagerström test for
nicotine dependence [35]. The participants’ health charac-
teristics were based on known nicotine withdrawal symp-
toms and weight gain as a main unfavourable health effect
[29, 36].
Statistical analysis
Categorical data were described using absolute and relative
frequencies and quantitative variables were summarised as
mean and standard deviation. Wald tests were used to as-
sess the statistical significance of estimates and to compare
related estimates.
The association of smoking abstinence failure (nonabsti-
nence) with a total of 39 variables was analysed using mul-
tilevel logistic regression models with random intercept for
training courses. These large numbers of potential predic-
tor variables were selected on the basis of the literature and
available data, in order to minimise the risk of confounding
of important effects and in order to find novel entry points
of potential relevance to improve quit rates.
Analyses were conducted both with a dichotomous non-
abstinence variable (with abstinence as reference group),
including participants according to the intention-to-treat
principle, and with a trichotomous nonabstinence variable
distinguishing reported nonabstinence from lack of report-
ing. The trichotomous variable was analysed with multi-
nomial logistic regression using “abstinence” as reference
and adjusted for clustering within training courses by use
of robust variance estimates. Models were built as follows.
First, each of the variables was investigated for association
with nonabstinence in minimally adjusted models, which
were only adjusted for basic sociodemographic determi-
nants (gender, age, work function, training language). Sec-
ond, all variables were included in fully adjusted models.
Five of the 39 variables had to be dropped from the models
owing to collinearity problems (recommendation at postin-
tervention; recommendation at 1-year follow-up; weight
gain at postintervention; weight gain at 1-year follow-up;
satisfaction with own collaboration).
Gender, age, training type and use of nicotine replacement
or pharmacological therapy were a priori considered as ef-
fect modifiers as they are important potential targets for
stratified adaption of smoking cessation interventions ac-
cording to existing evidence. Strata-specific estimates ac-
cording to gender, age, use of nicotine replacement and
training type were obtained by letting the corresponding
stratum variable interact with all other independent vari-
ables.
Associations were expressed as odds ratios (ORs) and 95%
confidence intervals (CIs).A p-values <0.05 was consid-
ered statistically significant for main effects and <0.1 for
interaction effects. Statistical analyses were performed us-
ing STATA SE 13.1 (Stata Corporation, TX, USA).
Results
Characteristics of study population
Overall, 1287 employees of 72 diverse companies partici-
pated in a total of 169 trainings given by 36 trainers. The
costs of the smoking cessation training amounted to about
550 Swiss francs per participant [12].
Baseline characteristics of participants and trainings are
presented in table 2, separately for (1) the intention-to-treat
(ITT) sample (n = 1287), (2) the sample with complete in-
formation on relevant pre- and postintervention questions
(n = 840; sample for studying determinants of quitting fail-
ure), and (3) the sample with incomplete information (n =
447). The identical grouping was used to show the postin-
terventional health characteristics and training opinion of
participants in table 3.
Of all 1287 participants, exclusions were as follows:
19.7% (n = 254) due to incomplete preintervention infor-
mation; 5.4% (n = 69) due to incomplete postintervention
information; 9.2% (n = 119) due to missing information on
postintervention abstinence, and 0.4% (n = 5) due to unre-
liable information on abstinence.
More men than women participated in this workplace-
based smoking cessation training (57.7%, n = 737). Over-
all, 21.5% (n = 277) of all participants were younger than
30 years and 50.0% (n = 643) were older than 40 years.
The level of nicotine dependence among participants was
high, with 58.6% (n = 726) smoking their first cigarette
within 30 minutes after waking up and an average of 18.7
cigarettes per day. The majority (95.3%, n = 1180) of the
employees learned about the cessation training through
company internal communication channels and 86.1% (n =
1064) were highly motivated to quit smoking. The postin-
tervention and 12-month follow-up questionnaire response
rates were 87.4% (n = 1 125) and 49.9% (n = 642), respec-
tively.
The subsample of participants for analysing determinants
of smoking cessation differed in several factors from the
sample excluded because of missing information (tables 2
and 3).
Quit rates
At the end of the training (postintervention), the rate of
self-reported abstinence was 83.4% (rate for all partici-
pants who answered the questionnaire) or 72.4% (accord-
ing to an ITT approach: rate in full sample considering
dropouts, non-responders and missing data on abstinence
as nonabstinent); 14.4% of 1287 subjects actively reported
failure to be abstinent; 13.2% of the sample did not re-
spond to this question). One year after the training (1-year
follow-up), the corresponding rates of self-reported absti-
nence were 37.4% and 18.6%, respectively (31.1% active-
ly reported relapse; 50.3% did not respond to this ques-
tion).
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The 12-month abstinence rates associated with the stan-
dard (n = 721) and the compact or super-compact pro-
gramme (n = 566) were similar (18.2% vs 19.1% according
to an ITT approach).
Risk factors for nonabstinence from smoking
Table 4 shows the results of the fully adjusted models
including 34 independent predictors. Only the results for
variables that were independently and statistically signif-
icantly (p <0.05) associated with either nonabstinence
postintervention or after 1 year of follow-up are shown
in this table (see supplementary tables S1A and S1B in
appendix 1 for the full set of associations in minimally
adjusted, fully adjusted and multinomial models). More
and different factors were associated with nonabstinence at
postintervention compared with the 1-year follow-up.
Gender was not associated with nonabstinence at any time-
point. Younger participants were less likely to abstain from
smoking in the long run (OR 0.83, 95% CI 0.72–0.95).
Smoking-related aspects showed some influence on non-
abstinence. Postintervention smoking relapse was related
to the number of years smoked (OR 1.06, 95% CI
1.00–1.12) and the number of cigarettes smoked per day
(OR 1.04, 95% CI 1.00–1.07). But only higher numbers of
cigarettes smoked per day at baseline were still significant-
ly associated with nonabstinence after 1 year (OR 1.03,
95% CI 1.00–1.06). Smoking a cigarette within 30 min-
utes after waking up showed a statistically nonsignificant
association with postintervention and long-term nonabsti-
nence. Failed long-term abstinence was particularly high in
participants who had tried to stop smoking within the 12
months preceding the current intervention (OR 2.69, 95%
CI 1.53–4.73).
With regard to training-related characteristics, only a poor
evaluation of learned techniques translated into a high non-
abstinence rate at 1-year follow-up (OR 0.65, 95% CI
0.43–0.98). In contrast, most of the training characteristics
analysed influenced nonabstinence in the short term, as ev-
idenced by postintervention quit rate (not attending the in-
formation event before the training, poor comprehensibili-
ty of training language, low satisfaction with training, but
not with trainer and considering learned techniques as not
helpful, all increased the likelihood of short-term smoking
relapse).
Self-reporting of sleeping troubles (OR 0.42, 95% CI
0.22–0.79) and increased appetite (OR 0.59, 95% CI
0.37–0.95) was found to decrease rather than increase non-
abstinence. But the presence of these or other symptoms
are likely to be the result of smoking cessation and they did
not predict nonabstinence in the long term.
No evidence was found for associations of nonabstinence
with work function, complete attendance of training ses-
sions, provision of cost or time for course by employer,
season when training began, group size of training, trainer
and participant gender difference, satisfaction with other
participants, increased irritability or anxiety, difficulty to
concentrate, depressed mood, increased nervousness or ag-
itation, slower heartbeat, and other withdrawal symptoms,
BMI, as well as use of nicotine replacement or other phar-
macological therapy (see tables S1A and S1B).
')*4- Baseline characteristics of participants and training in Enterprise Smoke-free, stratified by subsample of participants.
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Participant gender (female) 540 (42.3) 323 (38.5) 217 (49.7)
Age (years) 40.0 ± 10.7 39.4 ± 10.6 41.1 ± 10.9
Body mass index (kg/m2) 24.8 ± 4.4 24.9 ± 4.1 24.6 ± 5.0
Work function
Only employee 545 (44.2) 365 (43.5) 180 (45.8)
Only management or with employee together 409 (33.2) 283 (33.7) 126 (32.1)
Work function unknown 279 (22.6) 192 (22.9) 87 (22.1)
&57316/,-;-9516)6;:
Years smoked 20.1 ± 10.4 19.8 ± 10.0 20.8 ± 11.1
Cigarettes per day 18.7 ± 8.1 18.4 ± 7.8 19.2 ± 8.6
First cigarette after waking up (within 30 minutes) 726 (58.6) 484 (57.6) 242 (60.9)
 7;1=);176,-;-9516)6;:
Intention to stop smoking (within 30 days) 1064 (86.1) 749 (89.2) 315 (79.5)
Last smoke stop attempt (>1 year ago) 694 (56.0) 478 (56.9) 216 (54.0)
Attended information event 621 (54.2) 440 (52.4) 181 (59.2)
Attended all training sessions 857 (76.9) 675 (80.4) 182 (66.2)
Costs paid (by company) 1106 (88.5) 759 (90.4) 347 (84.6)
Time accounted (by participant) 893 (71.2) 594 (70.7) 299 (72.0)
'9)1616/,-;-9516)6;:
Training type (standard) 721 (56.0) 412 (49.0) 309 (69.1)
Language (German) 890 (69.2) 552 (65.7) 338 (75.6)
Season by training begin (winter) 547 (42.5) 341 (40.6) 206 (46.1)
Group size 8.6 ± 2.7 8.6 ± 2.7 8.5 ± 2.6
Trainer gender (female) 864 (67.1) 55.8 (66.4) 306 (68.5)
Trainer and participant gender (same) 619 (48.5) 419 (49.9) 200 (45.8)
ITT = intention to treat Data are given as mean ± standard deviation or n (%).
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Effect modification by age, gender, nicotine replace-
ment, and training type
Supplementary tables S2A and S2B (appendix 1) sum-
marises the association of determinants with 1-year nonab-
stinence stratified by gender, age, use of nicotine replace-
ment, and course type. Only the results for statistically
significant interactions in the main effects models (deter-
minants listed in table 4) are shown. Effect modifications
by gender, age or training type were observed for the as-
sociations of 1-year nonabstinence with the variables sat-
isfaction with trainer and increased appetite (all interaction
p <0.05). Interestingly, increased appetite was associated
with a higher likelihood of nonabstinence at the 1-year fol-
low-up in women (OR 2.36, 95% CI 1.17–4.75), but not
men. There was, furthermore, a suggestion that the statisti-
cally nonsignificant gender difference in quit rates may de-
pend on the use of nicotine replacement.
Discussion
To our knowledge, this is the first smoking cessation pro-
gramme in a workplace setting that was implemented in
the different languages and cultural contexts of a whole
country. A rate of self-reported abstinence under real-life
conditions of 18.6% with a full sample approach (ITT) at
12-month follow-up was achieved. The true success rate is
probably underestimated, given a response rate of 49.9%
and the conservative analysis approach in which all partic-
ipants with missing data on abstinence were considered as
nonabstinent. A higher abstinence rate could have been ex-
pected given the large percentage (86.1%) of highly moti-
vated participants at the beginning of the training.
The 12-month abstinence rates after smoking cessation re-
ported in the Cochrane reviews vary between 5 and 48%
for behavioural group interventions in workplace and other
settings [8, 10]. The study of Wenig et al. on an equivalent
smoking cessation programme, but implemented in a rou-
tine care instead of a workplace setting in Germany,
showed abstinence rates of 31.8% (ITT) at the 1-year fol-
low-up. The difference in setting, the higher response rate
at the 1-year follow-up (85.5% vs 49.9%) and a higher per-
centage of older participants (72.5% vs 47.5% older than
40 years), who are more likely to already exhibit smok-
ing related symptoms, can in part explain the higher ab-
stinence rate [5]. A 5-day plan for smoking cessation us-
ing similar group behavioural therapy in Switzerland with
volunteers, who responded to an announcement in the lo-
cal media, achieved an abstinence rate of 25% after 1 year
[21]. A workplace intervention for healthcare employees
in Switzerland, which was based on individual counselling
and pharmacological support, reached 24-month quit rates
of 37% (ITT). It consisted of intensive individual face-to-
face counselling and a much higher endorsement of phar-
macological support (93% vs 31% use of pharmacothera-
py). Additionally, a re-intervention was offered after failed
cessation or relapse. Nearly a quarter of the participants
used this opportunity one or more times during the 24
months of the programme [19]. The relatively low re-
sponse rate of 49.9% at 1-year follow-up in our study is
possibly due to voluntary participation in the evaluation
')*4- Health characteristics and opinion on training postintervention in Enterprise Smoke-free, stratified by subsample of participants.
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Withdrawal symptoms postintervention 1.9 ± 1.6 2.0 ± 1.6 1.7 ± 1.5
Sleeping troubles 234 (21.1) 199 (23.7) 35 (13.0)
Increased appetite 493 (44.5) 375 (44.6) 118 (43.9)
Increased anxiety 73 (6.6) 58 (6.9) 15 (5.6)
Increased irritability 427 (38.5) 339 (40.4) 88 (32.7)
Difficulty concentrating 171 (15.4) 130 (15.5) 41 (15.2)
Depressed mood 184 (16.6) 140 (16.7) 44 (16.4)
Increased nervousness or agitation 376 (33.9) 299 (35.6) 77 (28.6)
Slow heart beat 42 (3.8) 35 (4.2) 7 (2.6)
Other withdrawal symptoms 129 (11.6) 103 (12.3) 26 (9.7)
Weight gain postintervention 421 (40.8) 303 (38.1) 118 (49.8)
Weight gain at 1-year follow-up 325 (51.8) 267 (53.0) 58 (47.2)
Use of pharmacotherapy postintervention
None 745 (67.1) 577 (68.7) 168 (62.2)
NRT only 316 (28.5) 227 (27.0) 89 (33.0)
Supportive medications only 34 (3.1) 26 (3.1) 8 (3.0)
NRT and supportive medications 15 (1.4) 10 (1.2) 5 (1.9)
'9)1616/,-;-9516)6;:
Comprehensibility trainer language (1 = very low to 6 = very high) 5.8 ± 0.6 5.8 ± 0.7 5.9 ± 0.6
Satisfaction (1 = very low to 6 = very high)
With trainer 5.4 ± 0.7 5.4 ± 0.7 5.4 ± 0.7
With other participants 5.3 ± 0.8 5.3 ± 0.8 5.2 ± 0.8
With own collaboration 4.9 ± 0.9 5.0 ± 0.9 4.7 ± 1.0
With training content 5.1 ± 0.8 5.1 ± 0.8 5.1 ± 0.9
Many or nearly all learned techniques helped 722 (67.0) 582 (69.3) 140 (59.1)
Recommendation postintervention 1045 (95.7) 795 (96.5) 250 (93.3)
Recommendation at 1-year follow-up 567 (91.7) 455 (92.3) 112 (89.6)
ITT = intention to treat; NRT = nicotine replacement therapy Data are given as mean ± standard deviation or n (%).
"91/16)4)9;1+4- Swiss Med Wkly. 2017;147:w14500
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 6 of 15
process of the programme and a high proportion of incom-
plete questionnaires (sufficient for evaluation but not for
research and therefore excluded), the initial lower effort
to obtain follow-up questionnaires due to financial restric-
tions and the collection of data in the context of a scientific
evaluation rather than in a study planned from the start.
The low response rate as a relevant factor could partly ex-
plain the lower quit rate at 1-year follow-up in the full sam-
ple approach (ITT).
The interventions described, including ours, differ in target
population (e.g., socioeconomic status, professional back-
ground, age), context and type of intervention, as well
as cost of the intervention. These differences need to be
considered in assessing the cost-effectiveness of these dif-
ferent group interventions. Our data suggests that, for a
subsample of workers, a low-cost intervention may be suf-
ficient to achieve long-lasting quit rates. The optimal in-
tervention seems to depend on the personal characteristics
of the targeted smokers. Our data provide some guidance
as to which worker subgroups benefit from more intensive
and thus costly interventions. Concerning personal deter-
minants of smoking cessation, the results of this modern
smoking cessation programme suggest that younger and
more addicted smokers and those with a recent attempt to
quit need prolonged support in order to achieve long last-
ing abstinence. These results agree well with other studies
that showed that the number of years smoked is inverse-
ly related to quitting [20–22]. Improved quit rates could be
achieved, for example, through prolonged telephone coun-
selling and the opportunity of a re-intervention for partic-
ipants failing to stop smoking during the training or for
those with a smoking relapse [19]. Whether participants
with a long history of nicotine addiction also benefit from
complementary individual face-to-face counselling or per-
sonalised pharmacological cessation support in addition to
special attention during and after the training requires fur-
ther studies in the context of workplace interventions; in
this study, self-use of pharmacotherapy did not have an
impact on quit rate. The suggestions for additional inter-
ventions acknowledge the fact that tobacco dependence is
a chronic disease and often requires repeated intervention
and multiple attempts to quit [37]. That older participants
were shown to be more successful at sustaining abstinence
is comparable with other studies [5, 19]. Older persons
with health-related symptoms like breathlessness on exer-
tion were shown to more likely than those with chronic
sputum production to stay abstinent for 2 years [19].
The current study raises some concerns regarding the neg-
ative effect of compact course types on long-term absti-
nence. As compact course participants are overrepresented
among responders this needs further study. The discrep-
ancy between the associations of participants’ satisfaction
with trainer or dissatisfaction with training with nonabsti-
nence from smoking postintervention may be interpreted
as discontent with the training format and content, while
still acknowledging the trainers’ commitment to their ab-
')*4- Independent determinants of nonabstinence post-training and at 1-year follow-up.
#7:;16;-9=-6;176 
?-)9.7447><8
!76)*:;16-6+-=:)*:;16-6+- !76)*:;16-6+-=:)*:;16-6+-
-;-9516)6;: (reference group)
"%  8=)4<- "%  8=)4<-
Participant gender male (female) 0.68 0.40–1.14 0.14 0.95 0.63–1.43 0.79
Age in years 0.87 0.74–1.02 0.08 	 	B	 			
Years smoked 
	 
		B

 		 1.02 0.99–1.05 0.25
Cigarettes per day 
	 
		B
	 		 
	 
		B
	 		
First cigarette after waking up (after >60 minutes) 0.68 0.25
Within 31 to 60 minutes 1.33 0.62–2.86 1.18 0.70–1.99
Within 6 to 30 minutes 1.52 0.73–3.19 1.65 0.97–2.80
Within 5 minutes 1.23 0.48–3.10 1.40 0.68–2.88
Intention to stop (no intention to stop) 0.56 0.50
In the next 6 months 0.45 0.10–2.02 0.71 0.13–3.94
In the next 30 days 0.53 0.15–1.89 0.52 0.11–2.45
Currently not smoking 0.24 0.03–1.83 0.32 0.05–1.91
Last smoke stop attempt (no stop attempt) 0.68 			
Less than 12 months ago 1.30 0.68–2.51  
B
More than 12 months ago 1.05 0.59–1.88 1.41 0.92–2.15
Attended info. event before training (did not attend) 	 	
B	 		 0.93 0.60–1.44 0.75
Compact and super compact training (standard training) 0.50 0.25–1.01 0.05 1.52 0.91–2.56 0.11
Training language German (French) 0.56 0.30–1.05 0.07 0.82 0.49–1.36 0.44
Comprehensibility of language (1 = very low to 6 = very high) 		 	B	 		 1.04 0.80–1.36 0.75
Satisfaction with trainer (1 = very low to 6 = very high) 
	 
	B 		 0.78 0.56–1.08 0.14
Satisfaction with training (1 = very low to 6 = very high) 	 	B	 		 1.09 0.82–1.43 0.56
Many or nearly all learned techniques helped (none or only
few helped)
	 	B	
 			
 	 	B	 		
Sleeping troubles (no sleeping troubles) 	 	B	 			 0.74 0.49–1.12 0.15
Increased appetite (no increased appetite) 	 	B	 		 1.08 0.76–1.55 0.67
CI = confidence interval; OR = odds ratio The p-value is the overall p-value of the respective variable (Wald test). Restricted to participants with complete information in pre-
and postintervention questionnaire (n = 840) and adjusted to pre- and postintervention questionnaire variables: participant gender, age, body mass index, work function, years
smoked, cigarettes smoked per day, first cigarette smoked after waking up, intention to stop smoking, last smoke stop attempt, attendance to information event, attendance to all
training sessions, cost account, time account, training type, training language, season by training begin, group size, trainer gender, trainer and participant gender, comprehensibil-
ity of trainer language, satisfaction with trainer, others, and training, withdrawal symptoms (sleeping troubles, increased appetite, increased anxiety, increased irritability, difficulty
concentrating, depressed mood, increased nervousness or agitation, slower heartbeat, and other withdrawal symptoms), use of nicotine replacement or other pharmacological
therapy, number of helpful techniques learned.
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stinence attempt. In line with other studies, no associations
were found between abstinence and work function, cost or
time account, season in which training took place, group
size, trainer gender, trainer and participant gender differ-
ence, or satisfaction with others [5, 19].
With respect to symptoms, a higher likelihood of absti-
nence at the end of the intervention was associated with
sleeping problems and increased appetite. We assume that
these symptoms are markers of successful smoking cessa-
tion rather than a motivational factor to quit. Also, weight
gain was associated with abstinence at the postintervention
assessment in the minimally adjusted models, but could
not be analysed in the fully adjusted model owing to
collinearity problems. Therefore, we cannot draw any con-
clusions concerning the influence of weight gain on absti-
nence. Neither these nor other symptoms (anxiety, irritabil-
ity, poor concentration, depressed mood, nervousness or
agitation, slower heartbeat) were independently associated
with 1-year abstinence, either due to the low prevalence of
some of these withdrawal symptoms or because their as-
sessment after the course did not identify persons needing
additional support for long-term smoking cessation. This
may not be true for increased appetite, which was associat-
ed with a lower 1-year abstinence rate in women only. The
study of McKee et al. showed that women may perceive
risks such as postcessation weight gain more strongly than
men and are therefore less likely to be motivated to quit
smoking and more likely to relapse to smoking [17].
The strengths of this study are that it covers three culturally
diverse language regions, has a substantial sample size, a
real-life setting, and a relatively high postintervention re-
sponse rate. Furthermore, we distinguished between non-
response and not reported abstinence in a multinomial re-
gression analysis and thereby were able to evaluate the role
of nonresponse in associations between quit rates and their
determinants.
The limiting factors of this study include its observational
character and lack of a control group, the limited number
of workplace settings considered, the relative large number
of variables studied in comparison to the number of par-
ticipants, the small numbers of participants involved re-
garding some of the variables, the reliance on self-reported
abstinence without confirmation by carbon monoxide mea-
surements or cotinine testing, and its considerable nonre-
sponse rate at the 1-year follow up. The carbon monoxide
measurements were not undertaken because of limited fi-
nancial resources. A limitation of carbon monoxide is fur-
thermore its relative short half-life.
This type of study design and analyses in the absence of a
randomised intervention with a control group can provide
only suggestive, but not conclusive, evidence on associa-
tions between determinants and smoking cessation. Final-
ly, these results may not be applicable to other populations
and workplace settings.
In conclusion, this relatively low-cost intervention showed
that a reasonable percentage of smokers can be motivated
to achieve long-lasting smoking cessation in the context of
group behavioural therapy programmes offered in work-
place settings. However, young and heavy smokers po-
tentially benefit from re-intervention and additional indi-
vidual counselling. The problem of increased appetite and
subsequent weight gain after smoking cessation may need
specific attention in women.
Future studies are still needed to optimise a cost-effective
group-level yet personalised counselling approach. Addi-
tional factors deserve to be studied, such as the impact of
social support (spouse, family, friends, co-workers), work-
place environment (regulations, financial support/incen-
tive), trainer characteristics (experience, profession), and
other health issues (comorbidity, multiple drug use, mental
illnesses).
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')*4-&
  Independent determinants of nonabstinence in minimally adjusted models
 1615)44?
),2<:;-,
57,-4:
#7:;16;-9=-6;176 
?-)9.7447><8
 <4;14-=-447/1:;1+57,-4  <4;14-=-447/1:;1+57,-4
!76)*:;16-6+-=:)*:;16-6+- !76)*:;16-6+-=:)*:;16-6+-
-;-9516)6;:9-.-9-6+-/97<8
"%  8=)4<- "%  8=)4<-
Participant gender male (female) 	 	B	 		 0.97 0.69–1.37 0.86
Age in years 	 	B	 			
 	 	B
		 		
BMI 0.97 0.92–1.03 0.30 0.97 0.94–1.01 0.21
Only management or with employee together (only employee) 0.61 0.36–1.03 0.06 0.81 0.55–1.17 0.26
Work function unknown (only employee) 0.75 0.43–1.30 0.30 0.80 0.52–1.22 0.29
Years smoked 
	 
	B

 		
 1.02 0.99–1.05 0.18
Cigarettes per day 
	 
	B
	 			 
	 
	
B
	 			

First cigarette after waking up within 31 to 60 minutes (after >60 min-
utes)
1.49 0.74–3.00 0.27 1.35 0.84–2.16 0.21
First cigarette after waking up within 6 to 30 minutes (after >60 min-
utes)


 

B 		 
 
B	 			

First cigarette after waking up within 5 minutes (after >60 minutes)  
B 		
 
 
B 		

Intention to stop in the next 6 months (no intention to stop) 0.48 0.12–1.90 0.30 0.60 0.11–3.11 0.54
Intention to stop in the next 30 days (no intention to stop) 0.45 0.14–1.45 0.18 0.49 0.11–2.20 0.36
Intention: currently not smoking§ (no intention to stop) 0.20 0.03–1.34 0.10 0.30 0.05–1.65 0.17
Last smoke stop attempt less than 12 months ago (no stop attempt) 1.16 0.65–2.10 0.61  
B

 			

Last smoke stop attempt more than 12 months ago (no stop attempt) 0.99 0.59–1.66 0.96 1.33 0.90–1.98 0.15
Attended information event before training (did not attend) 0.86 0.55–1.35 0.51 0.97 0.69–1.36 0.85
Attended all training sessions (did not attend all) 1.33 0.78–2.25 0.29 0.74 0.48–1.14 0.17
Training costs born by participant (by company) 1.61 0.83–3.15 0.16 0.95 0.55–1.64 0.85
Training time born by participant (by company) 0.71 0.41–1.21 0.20 1.07 0.70–1.65 0.74
Compact and super compact training (standard training) 0.77 0.46–1.29 0.32 1.23 0.84–1.79 0.29
Training language German (French) 	 	B	 			
 1.04 0.73–1.48 0.82
Season winter (summer) 1.10 0.71–1.71 0.67 
 
	B	 		
Group size 0.99 0.92–1.07 0.84 0.97 0.92–1.03 0.38
Trainer gender male (female) 0.87 0.54–1.39 0.56 	 	B	 		
Trainer and participant same gender (different gender) 0.84 0.54–1.32 0.46 0.82 0.58–1.16 0.25
Comprehensibility of training language (1 = very low to 6 = very high) 0.80 0.62–1.04 0.10 0.96 0.74–1.24 0.74
Satisfaction with trainer (1 = very low to 6 = very high) 1.07 0.80–1.43 0.66 	 		B	 		
Satisfaction with others (1 = very low to 6 = very high) 1.04 0.79–1.37 0.77 0.91 0.73–1.14 0.40
Satisfaction with oneself (1 = very low to 6 = very high) 	 	B		 			
 	 	B	 			

Satisfaction with training (1 = very low to 6 = very high) 	 		B	 		 0.88 0.72–1.09 0.24
Many or nearly all learned techniques helped me (none or only few
helped)
	 	B	 			
 	 	B	 		
Recommended training at postintervention 0.67 0.26–1.71 0.40 0.41 0.12–1.37 0.15
Recommended training at 1-year follow-up 	 	
B		 		 	
 		B	 			
Sleeping troubles (no sleeping troubles) 	 	B	 		 0.95 0.65–1.38 0.79
Increased appetite (no increased appetite) 	 	B	 		
 1.05 0.76–1.46 0.75
Increased anxiety (no increased anxiety) 1.86 0.95–3.62 0.07  
	B 		
Increased irritability (no increased irritability) 0.89 0.58–1.37 0.61 0.98 0.70–1.36 0.89
Difficulty concentrating (no difficulty concentrating) 1.56 0.92–2.64 0.10 
 

B 		

Depressed mood (no depressed mood) 1.61 0.99–2.63 0.05 1.41 0.88–2.26 0.16
Increased nervousness or agitation (no increased nervousness or ag-
itation)
1.39 0.92–2.12 0.12 1.39 0.98–1.97 0.07
Slower heartbeat (no slower heartbeat) 0.68 0.20–2.34 0.54 1.56 0.64–3.84 0.33
Other withdrawal symptoms (no other withdrawal symptoms) 1.08 0.58–2.00 0.82 1.33 0.78–2.26 0.29
Weight gain at postintervention 		 	
B	 			
 0.80 0.57–1.12 0.19
Weight gain at 1-year follow-up 	
 		B	
 			
 		 		B	
 			

NRT only (no pharmacotherapy) 1.42 0.90–2.25 0.13 1.19 0.81–1.73 0.38
Supportive medications only
(no pharmacotherapy)
0.87 0.24–3.10 0.83 1.09 0.42–2.79 0.86
NRT and supportive medications
(no pharmacotherapy)
3.58 0.86–14.97 0.08 1.34 0.28–6.49 0.72
BMI = body mass index; CI = confidence interval; NRT = nicotine replacement therapy; OR = odds ratio The p-value is the overall p-value of the respective variable (Wald test).
* Restricted to participants with complete information in pre- and postintervention questionnaires (n = 840). The association of the outcomes with each of the determinants was
adjusted for participant gender, age, training language, and work function. § 30 participants that probably stopped smoking before beginning the training and succeeded in staying
abstinent until then.
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')*4-&
 Independent determinants of nonabstinence in fully adjusted models.
<44?),
2<:;-,
57,-4:
#7:;;9)1616/ 
?-)9
.7447>
<8
 <4;14-=-447/1:;1+57,-4  <4;14-=-447/1:;1+57,-4  <4;16751)4
57,-4
!76)*:;16-6+-=:)*:;16-6+- !76)*:;16-6+-=:)*:;16-6+- !76)*:;16-6+-=:)*:;16-6+- !76)*:;16-6+-=:)*:;16-6+-
-;-9516)6;: 9-.-9-6+-
/97<8
"%  8=)4<- "%  8=)4<- "%  8=)4<- "%  8=)4<-
Participant gender male (fe-
male)
0.68 0.40–1.14 0.14 0.95 0.63–1.43 0.80 0.86 0.52–1.42 0.56 1.07 0.62–1.84 0.80
Age in years 0.87 0.74–1.02 0.08 	 	B	 		
 	 	B	 		 	 	
B	 		

BMI 0.97 0.91–1.03 0.29 0.97 0.93–1.02 0.24 0.98 0.93–1.03 0.36 0.97 0.92–1.02 0.25
Only management or with
employee together (only em-
ployee)
0.61 0.35–1.06 0.08 0.81 0.53–1.24 0.34 0.99 0.60–1.63 0.97 0.65 0.40–1.06 0.08
Work function unknown (on-
ly employee)
0.73 0.40–1.33 0.30 0.71 0.45–1.13 0.15 0.76 0.47–1.23 0.27 0.69 0.40–1.22 0.20
Years smoked 
	 
		B

 		 1.02 0.99–1.05 0.25 1.02 0.99–1.06 0.22 1.01 0.98–1.05 0.52
Cigarettes per day 
	 
		B
	 		 
	 
		B
	 		 1.03 1.00–1.07 0.09 1.03 1.00–1.07 0.06
First cigarette after waking
up within 31 to 60 minutes
(after >60 minutes)
1.33 0.62–2.86 0.46 1.18 0.70–1.99 0.54 1.28 0.69–2.38 0.44 1.09 0.61–1.96 0.77
First cigarette after waking
up within 6 to 30 minutes
(after >60 minutes)
1.52 0.73–3.19 0.26 1.65 0.97–2.80 0.06 1.20 0.65–2.20 0.56 	 
B
 		

First cigarette after waking
up within 5 minutes (after
>60 minutes)
1.23 0.48–3.10 0.67 1.40 0.68–2.88 0.36 1.11 0.50–2.45 0.80 1.82 0.77–4.30 0.17
Intention to stop in the next
6 months (no intention to
stop)
0.45 0.10–2.02 0.30 0.71 0.13–3.94 0.69 0.55 0.08–3.61 0.53 1.02 0.17–6.20 0.98
Intention to stop in the next
30 days (no intention to
stop)
0.53 0.15–1.89 0.33 0.52 0.11–2.45 0.41 0.43 0.08–2.31 0.33 0.67 0.13–3.52 0.64
Intention: currently not
smoking§ (no intention to
stop)
0.24 0.03–1.83 0.17 0.32 0.05–1.91 0.21 	
 		B	 		 0.68 0.12–3.84 0.66
Last smoke stop attempt
less than 12 months ago (no
stop attempt)
1.30 0.68–2.51 0.43  
B 			
  
B 			 
 
B 			

Last smoke stop attempt
more than 12 months ago
(no stop attempt)
1.05 0.59–1.88 0.87 1.41 0.92–2.15 0.11 1.26 0.82–1.93 0.30 
 
	B 		
Attended information event
before training (did not at-
tend)
	 	
B	 		 0.93 0.60–1.44 0.75 0.92 0.59–1.46 0.74 0.95 0.56–1.61 0.86
Attended all training ses-
sions (did not attend all)
1.80 0.99–3.29 0.05 0.79 0.49–1.29 0.35 0.82 0.45–1.47 0.50 0.76 0.45–1.28 0.30
Training costs born by par-
ticipant (by company)
1.66 0.76–3.63 0.21 1.17 0.62–2.22 0.62 1.01 0.49–2.10 0.97 1.34 0.68–2.64 0.40
Training time born by partici-
pant (by company)
0.65 0.35–1.21 0.18 0.91 0.56–1.48 0.71 0.90 0.50–1.61 0.72 0.93 0.53–1.63 0.81
Compact and super compact
training (standard training)
0.50 0.25–1.01 0.05 1.52 0.91–2.56 0.11 
 

B
 		
 1.28 0.70–2.34 0.42
Training language German
(French)
0.56 0.30–1.05 0.07 0.82 0.49–1.36 0.44 	 	B	 		
 1.47 0.81–2.68 0.21
Season winter (summer) 1.35 0.81–2.25 0.25 1.33 0.91–1.96 0.14 1.39 0.90–2.15 0.13 1.25 0.81–1.94 0.31
Group size 1.01 0.92–1.11 0.79 0.96 0.89–1.03 0.27 0.97 0.90–1.05 0.42 0.95 0.86–1.04 0.25
Trainer gender male (fe-
male)
0.74 0.43–1.28 0.28 0.77 0.52–1.15 0.21 0.77 0.49–1.20 0.25 0.79 0.47–1.35 0.39
Trainer and participant same
gender (different gender)
0.81 0.49–1.32 0.39 0.80 0.54–1.17 0.25 0.76 0.48–1.19 0.23 0.86 0.53–1.39 0.53
Comprehensibility of training
language (1 = very low to 6
= very high)
		 	B	 		 1.04 0.80–1.36 0.75 1.13 0.81–1.58 0.47 0.98 0.76–1.27 0.88
Satisfaction with trainer (1 =
very low to 6 = very high)

	 
	B 		 0.78 0.56–1.08 0.14 0.76 0.53–1.08 0.13 0.81 0.56–1.16 0.25
Satisfaction with others (1 =
very low to 6 = very high)
1.60 0.79–1.53 0.02 0.78 0.76–1.29 0.14 0.76 0.78–1.34 0.13 0.81 0.73–1.24 0.25
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 <4;14-=-447/1:;1+57,-4  <4;14-=-447/1:;1+57,-4  <4;16751)4
57,-4
!76)*:;16-6+-=:)*:;16-6+- !76)*:;16-6+-=:)*:;16-6+- !76)*:;16-6+-=:)*:;16-6+- !76)*:;16-6+-=:)*:;16-6+-
-;-9516)6;: 9-.-9-6+-
/97<8
"%  8=)4<- "%  8=)4<- "%  8=)4<- "%  8=)4<-
Satisfaction with oneself (1 =
very low to 6 = very high)
– – – – – – – – – – – –
Satisfaction with training (1
= very low to 6 = very high)
	 	B	 		 1.09 0.82–1.43 0.56 1.15 0.83–1.58 0.41 1.03 0.77–1.38 0.85
Many or nearly all learned
techniques helped me (none
or only few helped)
	 	B	
 			
 	 	B	 		 0.69 0.43–1.09 0.11 	
 		B	
 		
Recommended training at
postintervention
– – – – – – – – – – – –
Recommended training at
1-year follow-up
– – – – – – – – – – – –
Sleeping troubles (no sleep-
ing troubles)
	 	B	 		
 0.74 0.49–1.12 0.15 0.75 0.47–1.20 0.23 0.73 0.47–1.12 0.15
Increased appetite (no in-
creased appetite)
	 	B	 		 1.08 0.76–1.55 0.67 1.03 0.67–1.59 0.90 1.14 0.73–1.78 0.57
Increased anxiety (no in-
creased anxiety)
1.61 0.73–3.56 0.24 1.73 0.71–4.20 0.23 1.26 0.44–3.65 0.67 2.32 0.83–6.45 0.11
Increased irritability (no in-
creased irritability)
0.74 0.42–1.28 0.28 0.78 0.53–1.16 0.23 0.87 0.54–1.41 0.58 0.71 0.45–1.12 0.14
Difficulty concentrating (no
difficulty concentrating)
1.54 0.85–2.79 0.15 1.65 0.94–2.90 0.08 1.70 0.87–3.34 0.12 1.60 0.87–2.97 0.13
Depressed mood (no de-
pressed mood)
1.69 0.93–3.08 0.09 0.93 0.54–1.60 0.79 0.99 0.57–1.74 0.99 0.87 0.48–1.58 0.64
Increased nervousness or
agitation (no increased ner-
vousness or agitation)
1.49 0.89–2.51 0.13 1.23 0.82–1.84 0.33 1.19 0.72–1.96 0.49 1.25 0.76–2.06 0.38
Slower heartbeat (no slower
heartbeat)
1.08 0.27–4.24 0.92 1.63 0.61–4.34 0.33 1.96 0.65–5.90 0.23 1.38 0.44–4.27 0.58
Other withdrawal symptoms
(no other withdrawal symp-
toms)
0.86 0.43–1.73 0.67 1.27 0.72–2.24 0.41 1.24 0.68–2.27 0.48 1.30 0.72–2.32 0.38
Weight gain at postinterven-
tion
– – – – – – – – – – – –
Weight gain at 1-year follow-
up
– – – – – – – – – – – –
NRT only (no pharmacother-
apy)
1.21 0.73–2.03 0.46 1.03 0.68–1.57 0.88 1.19 0.72–1.97 0.51 0.87 0.56–1.35 0.53
Supportive medications only
(no pharmacotherapy)
0.50 0.12–1.97 0.32 0.72 0.26–2.02 0.54 0.99 0.29–3.41 0.99 0.51 0.16–1.66 0.26
NRT and supportive medica-
tions
(no pharmacotherapy)
2.20 0.51–9.53 0.29 0.72 0.14–3.84 0.70 1.03 0.20–5.38 0.97 0.50 0.08–3.01 0.45
The p-value is the overall p-value of the respective variable (Wald test). * Restricted to participants with complete information in pre- and postintervention questionnaires (n =
840) and adjusted to pre- and postintervention questionnaire variables: participant gender, age, body mass index, work function, years smoked, cigarettes smoked per day, first
cigarette smoked after waking up, intention to stop smoking, last smoke stop attempt, attendance to information event, attendance to all training sessions, cost account, time
account, training type, training language, season by training begin, group size, trainer gender, trainer and participant gender, comprehensibility of trainer language, satisfaction
with trainer, others and training, withdrawal symptoms (sleeping troubles, increased appetite, increased anxiety, increased irritability, difficulty concentrating, depressed mood, in-
creased nervousness or agitation, slower heartbeat, and other withdrawal symptoms), use of nicotine replacement or other pharmacological therapy, number of helpful techniques
learned. § 30 participants that probably stopped smoking before beginning the training and succeeded in staying abstinent until then.
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')*4-& Stratified independent determi-
nants of nonabstinence at 1-year follow-up:
gender and age.
 )4-8)9;1+18)6; -5)4-8)9;1+18)6; 6;-9)+;176 A	?-)9:74, 	?-)9:74, 6;-9)+;176-;-9516)6;:9-.-9-6+-/97<8
"% 8=)4<- "% 8=)4<- 8=)4<- "% 8=)4<- "% 8=)4<- 8=)4<-
Participant gender male (female) – – – – – 0.85 0.60 1.19 0.58 0.48
Age in years 	
 		 0.79 0.05 0.99 – – – – –
Years smoked 1.02 0.34 1.02 0.55 0.99 0.99 0.67 1.01 0.33 0.42
Cigarettes per day 1.03 0.10 1.04 0.24 0.89 1.05 0.10 1.03 0.16 0.65
First cigarette after waking up (after >60 min-
utes)
0.20 		
Within 31 to 60 minutes 0.87 0.72 1.82 0.22 1.93 0.11 0.65 0.31
Within 6 to 30 minutes 1.38 0.40 2.40 0.06 1.46 0.34 1.92 0.13
Within 5 minutes 0.75 0.58  		 1.44 0.52 1.34 0.61
Intention to stop (no intention)* 0.81 0.43
In the next 6 months 2.50 0.37 – 0.97 0.75 0.82 0.24 0.31
In the next 30 days 1.53 0.63 – 0.97 0.38 0.40 0.43 0.48
Last smoke stop attempt (no attempt) 0.64 0.44
Less than 12 months ago  			
 2.13 0.14  			
 2.32 0.06
More than 12 months ago 1.50 0.16 1.17 0.68 1.46 0.22 1.49 0.25
Attended info event before training (did not at-
tend)
0.82 0.49 0.95 0.91 0.79 1.55 0.20 0.55 0.07 		
Compact and super compact training (standard
training)
1.43 0.29 1.23 0.69 0.81 1.63 0.23 1.32 0.50 0.73
Training language German (French) 0.95 0.90 0.94 0.89 0.98 0.71 0.44 0.93 0.85 0.67
Comprehensibility of language (1 = very low to
6 = very high)
0.84 0.35 1.57 0.11 		 0.86 0.58 1.18 0.37 0.30
Satisfaction with trainer (1 = very low to 6 =
very high)
0.68 0.09 0.81 0.50 0.65 1.15 0.55 	 		 		
Satisfaction with training (1 = very low to 6 =
very high)
1.25 0.23 0.93 0.78 0.36 0.87 0.50 1.37 0.15 0.12
Many or nearly all learned techniques helped
(none or only few helped)
0.70 0.22 0.59 0.17 0.71 0.67 0.23 0.62 0.12 0.82
Sleeping troubles (no sleeping troubles) 	 		 0.96 0.93 0.31 0.69 0.27 0.65 0.15 0.89
Increased appetite (no increased appetite) 0.85 0.51  		 		 1.43 0.22 0.94 0.83 0.31
OR = odds ratio p-values from the Wald test Restricted to participants with complete information in pre- and postintervention questionnaires (n = 840*) and adjusted to pre- and
postintervention questionnaire variables: participant gender, age, body mass index, work function, years smoked, cigarettes smoked per day, first cigarette smoked after waking
up, intention to stop smoking, last smoke stop attempt, attendance to information event, attendance to all training sessions, cost account, time account, training type, training
language, season by training begin, group size, trainer gender, trainer and participant gender, comprehensibility of trainer language, satisfaction with trainer, others and training,
withdrawal symptoms (sleeping troubles, increased appetite, increased anxiety, increased irritability, difficulty concentrating, depressed mood, increased nervousness or agitation,
slower heartbeat, and other withdrawal symptoms), use of nicotine replacement or other pharmacological therapy, number of helpful techniques learned. * 25 additional partici-
pants excluded from this analysis because category 4 “currently not smoking” of the variable “intention to stop smoking” could not be estimated in subgroup analysis (n = 815).
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')*4-& Stratified independent determinants of nonabstinence at 1-year follow-up: pharmacotherapy use and type of training.
!780)95)+7;0-9)
8?
#0)95)+7;0-9)8? 6;-9)+;176 &;)6,)9, 758)+; 6;-9)+;176
-;-9516)6;:9-.-9-6+-/97<8 "% 8=)4<- "% 8=)4<- 8=)4<- "% 8=)4<- "% 8=)4<- 8=)4<-
Participant gender male (female) 1.18 0.54 0.61 0.26 		 0.83 0.53 1.19 0.60 0.96
Age in years 		 		
 0.83 0.21 0.67 0.83 0.07 0.86 0.18 0.39
Years smoked 1.02 0.26 1.00 0.89 0.49 1.03 0.22 1.01 0.55 0.70
Cigarettes per day 
	 		 1.01 0.67 0.37 
	 		
 1.00 0.84 		
First cigarette after waking up (after >60
minutes)
0.16 0.29
Within 31 to 60 minutes 1.33 0.36 0.66 0.59 1.05 0.91 1.68 0.21
Within 6 to 30 minutes 1.65 0.13 1.36 0.66 1.14 0.74 
 		

Within 5 minutes 2.78 0.06 0.53 0.42 0.73 0.58 2.66 0.08
Intention to stop (no intention)* 0.36 0.64
In the next 6 months 0.59 0.58 – 0.99 1.33 0.79 – 0.97
In the next 30 days 0.61 0.56 – 0.99 0.78 0.78 – 0.97
Last smoke stop attempt (no attempt) 0.23 0.96
Less than 12 months ago 
 		 
 		
 
 		
  		
More than 12 months ago 1.25 0.42 1.47 0.38 1.33 0.38 1.38 0.32
Attended info event before training (did not
attend)
1.10 0.72 0.45 0.11 		 0.92 0.80 0.85 0.64 0.95
Compact and super compact training (stan-
dard training)
1.64 0.13 1.01 0.99 0.45 – – – – –
Training language German (French) 0.87 0.68 0.51 0.25 0.48 1.06 0.87 0.77 0.60 0.64
Comprehensibility of language (1 = very low
to 6 = very high)
1.30 0.15 0.83 0.47 0.14 1.45 0.09 0.77 0.30 		
Satisfaction with trainer (1 = very low to 6 =
very high)
	 		 1.13 0.75 0.24 0.80 0.38 0.74 0.25 0.84
Satisfaction with training (1 = very low to 6 =
very high)
1.11 0.54 1.03 0.93 0.96 1.08 0.76 1.07 0.72 0.98
Many or nearly all learned techniques
helped (none or only few helped)
0.69 0.14 0.48 0.12 0.48 0.70 0.26 0.69 0.22 0.99
Sleeping troubles (no sleeping troubles) 	 		 1.04 0.93 0.29 0.66 0.21 0.68 0.21 0.96
Increased appetite (no increased appetite) 1.34 0.21 0.80 0.58 0.23 
 		 0.73 0.25 		
OR = odds ratio p-values from the Wald test Restricted to participants with complete information in pre- and postintervention questionnaires (n = 840*) and adjusted to pre- and
postintervention questionnaire variables: participant gender, age, body mass index, work function, years smoked, cigarettes smoked per day, first cigarette smoked after waking
up, intention to stop smoking, last smoke stop attempt, attendance to information event, attendance to all training sessions, cost account, time account, training type, training
language, season by training begin, group size, trainer gender, trainer and participant gender, comprehensibility of trainer language, satisfaction with trainer, others and training,
withdrawal symptoms (sleeping troubles, increased appetite, increased anxiety, increased irritability, difficulty concentrating, depressed mood, increased nervousness or agitation,
slower heartbeat, and other withdrawal symptoms), use of nicotine replacement or other pharmacological therapy, number of helpful techniques learned. * 25 additional partici-
pants excluded from this analysis because category 4 “currently not smoking” of the variable “intention to stop smoking” could not be estimated in subgroup analysis (n = 815).
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